Literature DB >> 1442759

Short-term responsiveness of membranous glomerulopathy to cyclosporine.

A Guasch1, M Suranyi, L Newton, B M Hall, B D Myers.   

Abstract

We administered a 12-week course of cyclosporine (CsA) (4 to 6 mg/kg/24 h) to nephrotic patients with membranous glomerulopathy (MG). Nephrotic patients with minimal change nephropathy (MCN) served as a comparison group. We evaluated the effects of CsA on proteinuria, glomerular function, and the release of cytokines by peripheral blood mononuclear cells in culture. Proteinuria was restored to normal levels within 2 to 4 weeks in MCN. Proteinuria declined from nephrotic to subnephrotic levels (< 3,500 mg/24 h) in 10 of 14 patients with MG, also within 2 to 4 weeks of onset of therapy. The four nonresponders exhibited a rapidly progressive and presumably irreversible form of MG culminating in renal failure. On average, fractional clearances of albumin and IgG declined by 59% and 73% in MG (P < 0.005); corresponding declines in MCN were by 99% (P < .0001). Corresponding rates of glomerular filtration in each glomerular injury remained unchanged. A strong trend for proteinuria to relapse after CsA was withdrawn was evident in both disorders. The release of tumor necrosis factor (TNF)-alpha by mononuclear cells in culture was enhanced in each glomerular injury, both before and after the course of CsA. We conclude that the proteinuria in most cases of MG exhibits a responsiveness to CsA that is qualitatively similar to, but less complete than, that in MCN. The rapidity with which barrier function improves suggests a possible role for cell-mediated immune injury in MG.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1442759     DOI: 10.1016/s0272-6386(12)70259-7

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

1.  Effect of steroid and cyclosporine in membranous nephropathy that is resistant to steroid and/or cytotoxic treatment.

Authors:  Melahat Coban; Remziye Nur Eke; Filiz Kizilates; Secil Ucar; Fatih Dede
Journal:  Int J Clin Exp Med       Date:  2014-01-15

2.  Lupus-like membranous nephropathy: Is it lupus or not?

Authors:  Ramin Sam; Amit Joshi; Sam James; Kuang-Yu Jen; Firouz Amani; Peter Hart; Melvin M Schwartz
Journal:  Clin Exp Nephrol       Date:  2014-07-04       Impact factor: 2.801

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 4.  Controversies in the treatment of idiopathic membranous nephropathy.

Authors:  Meryl Waldman; Howard A Austin
Journal:  Nat Rev Nephrol       Date:  2009-07-07       Impact factor: 28.314

5.  Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients.

Authors:  Hua-Zhang Qin; Lei Liu; Shao-Shan Liang; Jing-Song Shi; Chun-Xia Zheng; Qing Hou; Ying-Hui Lu; Wei-Bo Le
Journal:  BMC Nephrol       Date:  2017-01-05       Impact factor: 2.388

Review 6.  Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia.

Authors:  Francesco Scolari; Federico Alberici; Federica Mescia; Elisa Delbarba; Hernando Trujillo; Manuel Praga; Claudio Ponticelli
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

7.  Chapter 7: Idiopathic membranous nephropathy.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06

8.  Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy.

Authors:  Maciej Goździk; Agnieszka Płuciennik; Anna Zawiasa-Bryszewska; Maja Nowicka; Zuzanna Nowicka; Małgorzata Wągrowska-Danilewicz; Ilona Kurnatowska
Journal:  Drug Saf Case Rep       Date:  2019-10-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.